60.60
-0.08 (-0.13%)
| Previous Close | 60.68 |
| Open | 60.72 |
| Volume | 1,198,590 |
| Avg. Volume (3M) | 1,765,085 |
| Market Cap | 11,727,554,560 |
| Price / Earnings (TTM) | 404.00 |
| Price / Earnings (Forward) | 10.24 |
| Price / Sales | 3.07 |
| Price / Book | 3.48 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 - 2 May 2025 |
| Profit Margin | 0.77% |
| Operating Margin (TTM) | 25.34% |
| Diluted EPS (TTM) | 0.150 |
| Quarterly Revenue Growth (YOY) | 16.30% |
| Quarterly Earnings Growth (YOY) | 0.10% |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 1.97 |
| Operating Cash Flow (TTM) | 335.34 M |
| Levered Free Cash Flow (TTM) | 619.45 M |
| Return on Assets (TTM) | 0.86% |
| Return on Equity (TTM) | 0.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Incyte Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 1.99% |
| % Held by Institutions | 96.77% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 92.00 (Guggenheim, 51.82%) | Hold |
| Median | 74.50 (22.94%) | |
| Low | 65.00 (Morgan Stanley, 7.26%) | Hold |
| Average | 77.00 (27.06%) | |
| Total | 1 Buy, 5 Hold | |
| Avg. Price @ Call | 63.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 24 Mar 2025 | 65.00 (7.26%) | Hold | 62.78 |
| Guggenheim | 18 Mar 2025 | 92.00 (51.82%) | Hold | 60.00 |
| Truist Securities | 18 Mar 2025 | 72.00 (18.81%) | Hold | 60.00 |
| Citigroup | 11 Feb 2025 | 88.00 (45.21%) | Buy | 66.33 |
| RBC Capital | 11 Feb 2025 | 68.00 (12.21%) | Hold | 66.33 |
| 23 Jan 2025 | 70.00 (15.51%) | Hold | 72.53 | |
| Stifel | 10 Feb 2025 | 77.00 (27.06%) | Hold | 68.30 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| TROTTA MATTEO | - | 62.08 | -537 | -33,337 |
| Aggregate Net Quantity | -537 | |||
| Aggregate Net Value ($) | -33,337 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 62.08 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TROTTA MATTEO | Officer | 25 Mar 2025 | Disposed (-) | 537 | 62.08 | 33,337 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |